Description du projet :
Biomarkers used in medicine, are a measurable indicator of some biological states or conditions and are a part of a relatively new clinical toolset categorised by their clinical applications. Their clinical role is in narrowing or guiding treatment decisions and follow a sub-categorization of being either predictive, prognostic or diagnostic. Biomarkers are often measured and evaluated using blood, urine or soft tissue to examine normal biological processes, pathogenic processes or pharmacologic responses to a therapeutic intervention.
Tuberculosis (TB) is a widespread condition that is even coming back to our regions. The current test techniques are based on an invasive procedure, a sputum test. A strategy has been developed for a triage test from blood, which abides the World Health Organisation’s target product profile (TPP) [1]. The four biomarkers that have been identified allowing for a TB triage test are IL-6, IL-8, IL-18 and VEGF. However, heavy and bulky equipment is needed to measure these biomarkers in their respective concentrations.
The ultimate goal of current endeavours to improve TB triage tests is to use a technique that can be performed at point-of-care in any endemic region, or any region for that matter. For achieving this objective, we have to take tackle the following unmet diagnostic needs:
I) A sub pg/ml detection limit
II) Fast and spontaneous signal generation iii) Cost-effectiveness of the technique
Research team within HES-SO:
Pallada Stavroula
Partenaires professionnels: Kandaswamy Djano, AeChem Life Technologies
Durée du projet:
01.01.2024 - 31.01.2025
Montant global du projet: 46'000 CHF
Statut: Ongoing
SWITCH edu-ID
Administration
